SiPhox Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
MIT-founded home blood testing company measuring 17 biomarkers via mail-in kits; Khosla-backed developing photonic chip for instant at-home results competing with Everlywell.
About
SiPhox Health is a home blood testing company founded by MIT scientists that provides mail-in blood test kits measuring 17 key biomarkers — inflammation markers (CRP, homocysteine), cardiovascular health (LDL, HDL, triglycerides, ApoB), metabolic health (HbA1c, glucose, insulin), and hormone levels (testosterone, DHEA, cortisol) — with results delivered within days and integrated with an app for trend tracking and health guidance. Founded in 2020 by Diedrik Vermeulen and Michael Dubrovsky, SiPhox Health is backed by Khosla Ventures, Intel Capital, and Y Combinator.\n\nSiPhox's current product uses at-home finger-prick blood collection with mail-in testing — customers order a $95 kit, collect a small blood sample at home, and mail it to SiPhox's CLIA-certified lab for analysis. The $16/month membership provides regular testing on a quarterly or customizable schedule, enabling biomarker trend monitoring over time rather than single point-in-time snapshots. The underlying technology vision is a photonic chip (silicon photonics-based biosensor) that would enable instant at-home blood analysis without lab processing, with FDA clearance targeted for 2026.\n\nIn 2025, SiPhox Health competes in the home diagnostics and consumer health testing market with Everlywell (the leading at-home test kit brand), Function Health (comprehensive blood panel membership), InsideTracker, and traditional lab companies (LabCorp, Quest Diagnostics) for consumer blood testing. The longevity and proactive health monitoring movement has driven demand for comprehensive biomarker testing beyond what annual physicals provide. The potential photonic chip breakthrough would represent a significant technological leap — enabling truly point-of-care diagnostics without lab infrastructure. The 2025 strategy focuses on growing the biomarker panel subscription business, advancing the photonic chip development toward FDA clearance, and building clinical evidence for the personalized health intervention recommendations.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.